SCHEMBL4486775

SCHEMBL4486775

Cc1cc(=O)c(-c2ccc(-c3cccc(C(F)(F)F)c3)nc2)c(C)[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.46
SLC11A2 P49281 1/20 0.44
KDM1A O60341 2/20 0.44
MAOB P27338 2/20 0.44
XDH P47989 1/20 0.44
DHODH Q02127 1/20 0.43
SCN2A Q99250 3/20 0.43
IDO1 P14902 1/20 0.42
IKBKB O14920 1/20 0.42
PIN1 Q13526 1/20 0.41
CDC7 O00311 1/20 0.41
GRIN1 Q05586 2/20 0.40
GRIN2B Q13224 2/20 0.40
MAOA P21397 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
GABRA1 P14867 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13761994 0.88 MAPT (0.43) SLC2A1SLC11A2KDM1AMAOBSCN2A
SCHEMBL13754678 0.83 HPGDS (0.48) DHODHKDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL4492018 0.82 SLC2A1 (0.51) SLC2A1SLC11A2KDM1AMAOBXDH
SCHEMBL4493390 0.82 SLC2A1 (0.66) SLC2A1SLC11A2KDM1AMAOBXDH
SCHEMBL5096515 0.80 SLC2A1 (0.51) SLC2A1SLC11A2GRIN1GRIN2B
SCHEMBL4471452 0.80 KDM1A (0.44) SLC11A2KDM1AMAOBXDHDHODH
SCHEMBL4478658 0.78 MAT2A (0.40) SCN2A
SCHEMBL9454944 0.76 MAPT (0.53) SLC11A2DHODHMAPT
SCHEMBL4486777 0.75 SCN2A (0.40) SLC11A2MAOBXDHSCN2AIKBKB
SCHEMBL3395824 0.74 KDM1A (0.40) KDM1ADHODHGRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885SLC11A2 1320/4885KDM1A 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.